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Approximately 1 out of 8 women in the United States will develop invasive breast cancer over 
the course of their lifetime. Breast cancer has a greater potential of being cured if diagnosed in 
the earlier phases. We evaluated three well-recognized biomarkers, GLUL, GLS, and Cav 
1(glutamine synthetase, glutaminase, caveolin-1) in 14 TMA (tissue Microarrays). The tissues 
were normal breast and various subtypes of breast carcinoma by immunohistochemistry (IHC) to 
determine expression and localization in cancerous tissues in breast carcinoma cases. 
Approximately 80 to 90 breast biopsies in each of the 14 breast TMA immunostaining were 
evaluated with the GLUL, GLS, and Cav 1 antibodies. With GLS, immunostaining was seen in 
most tumor cells (mainly cytoplasm and nucleus) and the stain was clean with no background 
except in cases that had lymphocytes in the core along with the tumor cells. With GLUL, 
immunostaining was seen in most tumor cells (mainly cytoplasm and nucleus) and the stain was 
clean with no background except in cases that had lymphocytes in the core along with the tumor 
cells. Cav1 was seen only in the endothelial cells in blood vessel walls and some smooth muscle 
cells in small arterioles in the stroma and surrounding normal ducts, DCIS, and some invasive 
carcinoma tumor clusters. This information from the immunostains was obtained after analyzing 
14 tissue microarrays which is not only time effective but cost effective when analyzing multiple 
research cases from cancer patients. The data for the three antibodies are currently being 
analyzed by the biostatistics core group and correlated with the severity of the breast cancer 
disease with multiple patient demographics. 
 
